United States: AIA Litigation Strategies
Last Updated: July 24 2012
Article by Brinks Hofer Gilson & Lione

The conversion from the longstanding first-to-invent system to a first-inventor-to-file system for granting patent rights may be the most significant change in legal practice to be imposed by the Leahy-Smith America Invents Act (AIA). But the AIA's full effect on patent litigation will not completely manifest itself for many months—if not years—after the AIA is fully implemented on March 16, 2013.

However, since enactment of the AIA began on September 16, 2011, several provisions are already affecting litigation and several that become effective on the next implementation date, September 16, 2012, will also have consequences. Below, we detail the AIA provisions most likely to affect litigation, and offer strategies to address these potential situations.

Provisions Already in Effect

35 USC § 299: Restrictions on Joinder
To the relief of many potential defendants, the AIA includes a key provision restricting joinder in a single patent infringement lawsuit.
Under 35 USC § 299, with certain exceptions, a patent owner cannot combine accused infringers into a single suit as defendants or counterclaim defendants, or have their suits consolidated for trial solely on the basis of allegations that each defendant has infringed the same patent or patents. Parties may be joined as defendants in an infringement suit only if they are jointly or separately liable with respect to specific acts, events or questions common to all defendants.

Impact on litigation: This provision makes it more difficult for non-practicing entities (NPEs) to enforce patent rights against multiple alleged infringers in a single lawsuit. Previously, paying only a single filing fee, an NPE could compel a large group of defendants to pay significant settlements rather than undertake the costly and difficult coordination of a complex multi-party legal defense. Such cases were problematic, perceived by some policymakers as providing financial benefits to NPEs without advancing innovation or otherwise providing economic or social value.

However, NPEs or other plaintiffs will still have the option of requesting a Section 337 investigation at the U.S. International Trade Commission (ITC), which has no restriction on naming multiple defendants.

Litigation strategies: Counsel will be able to pursue several strategies if their company is named in a large group of unrelated defendants:

  • File a motion for misjoinder, if no act, event or question of fact is common to all defendants.
  • Request a stay of proceedings in light of co-pending litigation against another defendant.
  • File a request for multi-district litigation under 28 U.S.C. § 1407, to transfer related cases to a common jurisdiction for consolidation or coordination of pre-trial proceedings, including claim construction.
  • Agree to consolidation for pretrial proceedings only.
  • Sign joint defense agreements with other defendants to share legal strategies and defense information.
     

35 USC § 292: False Patent Marking
In 2009, in Forest Group Inc. v. Bon Tool Co., 590 F3d 1295 (Fed. Cir. 2009), the U.S. Court of Appeals for the Federal Circuit held that any person could file a false marking suit and force defendants to pay up to $500 per instance of false marking, with damages to be evenly split between the plaintiff and the U.S. government. In the wake of this decision, hundreds of plaintiffs emerged with false marking claims.

The AIA eliminates recovery of damages for a product marked with an expired patent unless the plaintiff can prove a competitive injury. As a result, within days of the AIA's enactment, many pending false marking cases were dismissed.

Impact on litigation: With Section 292 of the AIA, false marking will again become an infrequent claim, as a plaintiff must now prove that a product marked with an expired patent has caused competitive injury.

Litigation strategies: In the event that a company is sued for false marking, counsel may be able to move to dismiss on the basis of lack of competitive injury. For companies seeking to file a false marking claim, they will need to show proof of competitive injury.

35 U.S.C. § 282(3): Best Mode Defense
The AIA eliminates the longstanding option for alleged patent infringers to argue that a patent owner failed to disclose the "best mode" of practice when prosecuting their patent. As a result, a plaintiff can move to dismiss any best mode affirmative defenses. Companies accused of infringement may attempt to transform the best mode defense into a separate 35 U.S.C. § 112 defense of invalidity on the basis of indefiniteness, lack of enablement or inadequate written description in the patent in dispute.

Provisions Implemented on September 16, 2012

35 U.S.C. §§ 311-19: Inter Partes Review, Not Inter Partes Reexamination
Under the AIA, post-grant proceedings are available to any petitioner for up to nine months after grant of a patent. With the exception of business method patents and some software patents, after the nine-month period has elapsed, a petitioner seeking to invalidate a patent through a USPTO proceeding must petition for inter partes review. Such petitions are permitted nine months after the grant date of a patent or reissued patent, or after the date of termination of a post-grant review.

To pursue an inter partes review, however, the petitioner must show a "reasonable likelihood" that at least one of the claims in the patent in dispute is unpatentable. Filing fees begin at $27,200 and grow significantly if the review includes more than 20 claims. The inter partes review cannot be anonymous, and it must challenge specific claims.

Additionally, estoppel applies to the party that requests an inter partes review. Any issue raised or that reasonably could have been raised during post-grant review cannot be subsequently raised by the requester at the USPTO, in court or in an investigation at the ITC. Furthermore, the requester cannot afterwards request an ex parte reexamination.

Impact on litigation: To avoid the estoppel rules and high fees for inter partes reviews, some companies may prefer to pursue ex parte reexaminations, which are still an option under the AIA. We may therefore see a surge of requests for inter partes reexaminations before the September deadline.

Litigation strategies: Defendants in a current patent infringement case should consider filing for an inter partes reexamination before September 16, 2012, as this proceeding may be more favorable for some defendants than the inter partes review. After September 16, defendants should consider filing for an ex parte reexamination as an alternative to an inter partes review.

35 U.S.C. Chapter 32, §§ 321-29: Transitional Post-Grant Review Period for Business Method Patents
Business method patents have long been subject to legal debates, most notably in the financial sector and in Bilski v. Kappos. The AIA is expected to have a dramatic impact on cases because of the special provisions aimed at financial business method patent disputes.

The AIA gives a defendant accused of business method patent infringement the option of requesting a post-grant review of prior art as much as a year after the infringement suit is filed. A petitioner under this transitional program is required to show a degree of certainty (that it is more likely than not) that their position will prevail on at least one of the claims. Also important, prior art can include not only patents and printed publications, but also non-published knowledge or use prior to the invention. Furthermore, this transitional post-grant review imposes less estoppel than for other types of patents; during trial or an ITC investigation, petitioners are only barred from raising issues that were previously raised during the post-grant review; they are free to introduce issues that could have been raised—but were not—during post-grant review. Petitioners can file an interlocutory appeal if the district court denies a request to stay the litigation.

This option will only be available for business method patents until September 16, 2020, eight years after this section of the AIA becomes effective on September 16, 2012. Once this eight-year window closes, it will not be reopened except by an act of Congress.

Impact on litigation: Defendants in business method patent suits are likely to file for a post-grant review with a motion to stay the litigation.

Litigation strategies: If a company is a defendant in a business method patent suit, counsel should give serious consideration to using this provision to speed up resolution of any validity issues. Defendants should also consider petitioning for other reexamination proceedings as well before the enactment date of September 16, 2012.

35 U.S.C. § 257 Supplemental Examination
At any time, a patent owner may file a request for supplemental examination with the USPTO to reexamine the patent to determine whether any "substantial new question of patentability" exists. Within three months of receiving such a request, the USPTO must respond, and reexamination procedures will follow thereafter.

Supplemental examination enables a patent owner to "cure" published patents by reexamining the issued patent in light of additional and potentially invalidating information.

Impact on litigation: With a fee in excess of $20,000, supplemental examination will likely be used only for important patents. For example, a plaintiff might file for supplemental examination during litigation if the defendant has presented evidence in support of an inequitable conduct defense, and will have the opportunity to supplement or amend their published patent.

Litigation strategies: A patentee plaintiff may respond to an inequitable conduct defense by filing a supplemental examination to "cure" its patent. The defendant should consider filing a reexamination or inter partes review to publicize its side of the story before the USPTO issues a ruling.

35 U.S.C. § 102: Provisions to be Implemented on March 16, 2013
The AIA's conversion to a first-inventor-to-file system, is manifested in Section 102 provisions concerning prior art. In general, for applications filed on or after March 16, 2013, the patent filing date and the invention date are one and the same. Any information published or otherwise disclosed anywhere in the world before the filing date is considered to be prior art.

Impact on litigation: Section 102's impact on litigation will remain unclear until it is fully effective.

* * *

This Strategy Briefing is intended to provide information of general interest to the public and is not intended to offer legal advice about specific situations or problems. Brinks Hofer Gilson & Lione does not intend to create an attorney-client relationship by offering this information and review of the information shall not be deemed to create such a relationship. You should consult a lawyer if you have a legal matter requiring attention. For further information, please contact a Brinks Hofer Gilson & Lione lawyer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

More Popular Related Articles on Food, Drugs, Healthcare, Life Sciences from USA
By now you may have heard the news about a number of changes on the horizon for the Health Insurance Portability and Protection Act.
Whether you are an employer that provides health insurance for your employees, a business in the growing healthcare industry, a hospital, or other medical provider—or you provide services to any of those entities—you need to know about changes to the privacy and security rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA).
A summary of the most recent health care reform implementation updates.
In April 2013, the U.S. Department of Justice announced the settlement of five investigations with healthcare providers.
Understanding the complexities of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules is often a challenge for health care providers and consumers.
Marilyn Tavenner received bipartisan support from members of the Senate Committee on Finance in her confirmation hearing to lead the Centers for Medicare and Medicaid Services (CMS) though a full Senate vote is being held up, the president released his FY 2014 budget proposal with health care reform and specified reimbursement reductions to providers and manufacturers totaling $400 billion over 10 years sprinkled throughout it, and Department of Health and Human Services (HHS) Secretary Sebelius
The Office of Inspector General for the Department of Health and Human Services has recently issued an updated Special Advisory Bulletin on the Effect of Exclusion from Participation in Federal Health Care Programs.
On Tuesday, the North Carolina legislature has enacted into law, pending the governor's signature, a prohibition on the use of most favored nations clauses in contracts between commercial health insurers and providers.
 
In association with
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
Accounting and Audit
Anti-trust/Competition Law
Consumer Protection
Corporate/Commercial Law
Criminal Law
Employment and HR
Energy and Natural Resources
Environment
Family and Matrimonial
Finance and Banking
Food, Drugs, Healthcare, Life Sciences
Government, Public Sector
Immigration
Insolvency/Bankruptcy, Re-structuring
Insurance
Intellectual Property
International Law
Litigation, Mediation & Arbitration
Media, Telecoms, IT, Entertainment
Privacy
Real Estate and Construction
Strategy
Tax
Transport
Wealth Management
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.